Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :837
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed318    
    Printed4    
    Emailed0    
    PDF Downloaded25    
    Comments [Add]    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 2020  |  Volume : 57  |  Issue : 1  |  Page : 13-17

Efficacy and safety of apatinib monotherapy in elderly patients with advanced metastatic non-small cell lung cancer


1 Department of Cardiothoracic Surgery, Huanggang Central Hospital, Huanggang, Hubei, China
2 Department of Oncology, The First People's Hospital of Jingzhou, Jingzhou, China

Correspondence Address:
Hongtao Li
Department of Oncology, The First People's Hospital of Jingzhou, Jingzhou
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijc.IJC_614_18

Rights and Permissions

Objective: No effective and definitive chemotherapeutic regimen has been established in patients with non-small cell lung cancer (NSCLC) who failed second-line treatment. The aim of this study was to evaluate apatinib, a VEGFR-2 inhibitor, as monotherapy in elderly patients with advanced metastatic NSCLC. Methods: We evaluated the efficacy and safety of apatinib in elderly patients (≥65 years old) with advanced metastatic NSCLC who failed second-line treatment from 2015 to 2016 in Huanggang Central Hospital. Survival analysis was performed by the Kaplan–Meier method. Toxicities were evaluated according to the National Cancer Institute Common Toxicity Criteria version 4.0. Results: Twenty patients were included in the present study. Two patients achieved partial response, and 9 achieved stable disease, representing a response rate of 10% and a disease control rate of 55%. Median progression-free survival and overall survival were 2.8 and 6.0 months, respectively. The toxicities associated with apatinib were generally acceptable with a total grade 3/4 toxicity of 50%. Conclusion: Apatinib is an optional choice as salvage treatment in elderly patients with advanced metastatic NSCLC, with modest efficacy and acceptable toxicities.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow